Applied Precision, along with Indiana University, are excited to announce the installation of a new DeltaVisionOMX imaging system in the Light Microscopy Imaging Center in Bloomington, Indiana. The DeltaVision|OMX is a ground-breaking, three dimensional, super-resolution microscopy system that more than doubles the optical resolution of traditional light microscopy. This super-resolution capability is especially important to cell biologists and microbiologists seeking to study objects and events that lie beyond the limits of conventional microscopy methods.

Read the full story here

At the congress of the European Societey of Cardiology (ESC) 2010, Siemens will present new image processing software that helps cardiologists and cardiac surgeons perform transcatheter aortic valve implantations (TAVI): Syngo Aortic ValveGuide automatically reconstructs a 3D representation of the aortic root from CT-like cross-sectional images acquired with the angiography system. The software selects anatomical landmarks as the coronary ostia, for instance, and overlays the 3D image with two-dimensional images acquired during live fluoroscopy.

Read the full story here

Boston Scientific Corporation has announced the start of patient enrollment in the EVOLVE clinical trial, which is designed to assess the safety and performance of its fourth-generation SYNERGY™ Coronary Stent. The SYNERGY Stent uses a bioabsorbable PLGA polymer and everolimus drug formulation to create a thin, uniform coating confined to the outer surface of the stent. Once the drug has been delivered, the bioabsorbable coating resorbs into the body, leaving behind only a bare-metal stent.

Read the full story here

Advanced Cell Diagnostics, Inc. (ACD) announces the launch and immediate availability of RNAscope™ FFPE Assay Kit, a line of RUO (Research-Use-Only) products designed to detect RNA biomarkers in routine Formalin-Fixed, Paraffin-Embedded (FFPE) tissue specimens with single molecule sensitivity. The products are intended to be used by translational clinical researchers studying biomarkers in disease tissues and exploring their potential for diagnostic applications. It is a robust and standardized manual assay in ready-to-use format.

Read the full story here

AdvanDx announced the launch of its CE-IVD marked GNR Traffic Light™ PNA FISH® test in Europe. GNR Traffic Light PNA FISH is the first-ever test capable of simultaneously identifying Escherichia coli, Klebsiella pneumoniae and Pseudomonas aeruginosa directly from positive blood cultures in less than 90 minutes. The GNR Traffic Light is the latest addition to AdvanDx’s easy-to-use, molecular-based PNA FISH diagnostics platform designed to provide rapid, therapy-guiding results.

Read the full story here

RegeneRx Biopharmaceuticals, Inc. has announced that Thymosin beta 4 (TB4), administered to rats after embolic stroke, improved neurological functional outcome compared to control animals. The research was performed under a Material Transfer Agreement between RegeneRx Biopharmaceuticals, Inc. and the Henry Ford Health System. Improvement in neurological function was measured at various time intervals over a seven week period and was statistically significant.

Read the full story here

Eisai Inc. has announced that the FDA has accepted for review Eisai’s NDA for BANZEL® (rufinamide) Oral Suspension (40 mg/mL). The proposed indication is for the adjunctive treatment of seizures associated with Lennox-Gastaut syndrome (LGS) in children four years and older and adults. The application is based on data from a study designed to demonstrate the bioequivalence of the oral suspension formulation to the currently marketed BANZEL tablet formulation (400 mg).

Read the full story here

NHS Central Lancashire’s community matrons have introduced an innovative remote patient care management tool to help chronically ill patients in Preston monitor and manage their health at home and remain independent for longer. The technology is currently being piloted with 40 patients with chronic obstructive pulmonary disease (COPD). If successful, NHS Central Lancashire aims to expand the programme to help patients with other chronic illnesses such as diabetes, hypertension and heart failure across central Lancashire.

Read the full story here

By emulating nature’s design principles, a team at Harvard’s Wyss Institute for Biologically Inspired Engineering, Harvard Medical School and Dana-Farber Cancer Institute has created nanodevices made of DNA that self-assemble and can be programmed to move and change shape on demand. In contrast to existing nanotechnologies, these programmable nanodevices are highly suitable for medical applications because DNA is both biocompatible and biodegradable. The work appears in the June 20 advance online Nature Nanotechnology.

Read the full story here

Using lab mice genetically bred to express immune cell proteins in different fluorescent colors, researchers at Beth Israel Deaconess Medical Center (BIDMC) and Professor of Medicine at Harvard Medical School (HMS) have developed a new imaging system that differentiates protective and destructive T-cells. This has enabled them to assess the health of transplanted tissue by visualizing immune cell responses in real time.

Read the full story here